Clinical trial NCT01561586 - References

Cervical Cancer — Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

Citation(s)

•   Agresti A
  A survey of exact inference for contingency tables. Statistical Science. 1992; 7: 131-177.
•   Bonomi AE, Cella DF, Hahn EA, Bjordal K, Sperner-Unterweger B, Gangeri L, Bergman B, Willems-Groot J, Hanquet P, Zittoun R
  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res. 1996 Jun;5(3):309-20.
•   Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ
  Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Aug;3(8):1079-85.
•   Cantor A
  Extending SAS Survival Analysis Techniques for Medical Research. Vol. 103. SAS Institute Inc. Cary, NC; 1997.
•   Cantor AB, Shuster JJ
  Parametric versus non-parametric methods for estimating cure rates based on censored survival data. Stat Med. 1992 May;11(7):931-7.
•   Cantor AB
  Sample size calculations for the log rank test: a Gompertz model approach. J Clin Epidemiol. 1992 Oct;45(10):1131-6.
•   Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al
  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9.
•   Cella DF, Wiklund I, Shumaker SA, Aaronson NK
  Integrating health-related quality of life into cross-national clinical trials. Qual Life Res. 1993 Dec;2(6):433-40.
•   Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration
  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008 Dec 10;26(35):5802-12. doi: 10.1200/JCO.2008.16.4368. Epub 2008 Nov 10. Review.
•   Chumworathayi B, Suprasert P, Charoenkwan K, Srisomboon J, Phongnarisorn C, Siriaree S, Cheewakriangkrai C, Tantipalakorn J, Kiatpeerakul C, Pantusart A
  Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance. J Med Assoc Thai. 2005 Nov;88(11):1483-92.
•   Cleeland CS, Ryan KM
  Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994 Mar;23(2):129-38. Review.
•   Eremenco SL, Cella D, Arnold BJ
  A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005 Jun;28(2):212-32.
•   Garcia AA, Blessing JA, Darcy KM, Lenz HJ, Zhang W, Hannigan E, Moore DH
  Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study. Gynecol Oncol. 2007 Mar;104(3):572-9. Epub 2006 Oct 17.
•   Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ
  Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6.
•   Huang HQ, Brady MF, Cella D, Fleming G
  Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93.
•   Ikushima H, Osaki K, Furutani S, Yamashita K, Kawanaka T, Kishida Y, Iwamoto S, Takegawa Y, Kudoh T, Nishitani H
  Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiat Med. 2006 Feb;24(2):115-21.
•   Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D
  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61. Erratum in: N Engl J Med 1999 Aug 26;341(9):708.
•   Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ
  A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003 Sep;68(3):217-26. Review.
•   Lachin JM
  Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000 Jun;21(3):167-89. Erratum in: Control Clin Trials 2000 Oct;21(5):526.
•   Lan KKG
  , DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663
•   Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore DH, Monk BJ, O'Connor DM
  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005 Nov 20;23(33):8289-95. Epub 2005 Oct 17.
•   Maduro JH, Pras E, Willemse PH, de Vries EG
  Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003 Dec;29(6):471-88. Review.
•   McQuellon RP, Thaler HT, Cella D, Moore DH
  Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 May;101(2):296-304. Epub 2006 Jan 10.
•   Mitsuhashi A, Uno T, Tanaka N, Suzuka K, Tate S, Yamazawa K, Matsui H, Yamamoto S, Ito H, Sekiya S
  Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma. Gynecol Oncol. 2005 Jan;96(1):194-7.
•   Monk BJ, Huang HQ, Cella D, Long HJ 3rd; Gynecologic Oncology Group Study
  Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4617-25. Epub 2005 May 23. Erratum in: J Clin Oncol. 2005 Nov 20;23(33):8549.
•   Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG
  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1137-43.
•   O'Brien PC, Fleming TR
  A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56.
•   Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D
  Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002 Feb 15;20(4):966-72.
•   Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS
  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13.
•   Pocock SJ, Simon R
  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975 Mar;31(1):103-15.
•   Quasthoff S, Hartung HP
  Chemotherapy-induced peripheral neuropathy. J Neurol. 2002 Jan;249(1):9-17. Review.
•   Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S
  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53. Erratum in: N Engl J Med 1999 Aug 26;341(9):708.
•   Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, Choi SC, Cho CK, Nam BH, Lee ED
  Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e577-81. doi: 10.1016/j.ijrobp.2011.05.002. Epub 2011 Aug 11.
•   Schoenfeld DA, Richter JR
  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982 Mar;38(1):163-70.
•   Siegal T, Haim N
  Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990 Sep 15;66(6):1117-23.
•   Thigpen T, Shingleton H, Homesley H, LaGasse L, Blessing J
  cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1549-55.
•   Watanabe Y, Nakai H, Shimaoka M, Tobiume T, Tsuji I, Hoshiai H
  Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. Int J Clin Oncol. 2006 Aug;11(4):309-13.
•   Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY
  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999 May;17(5):1339-48.
•   Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, Shin HC, Wang XS, Cleeland CS
  Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology. 2004;66(6):439-44.

Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

Details for clinical trial NCT01561586